INS and diabetes mellitus: Glitazones or thiazolidinediones are a class of insulin-sensitizers used in the treatment of type-2 diabetes mellitus (T2DM).1 They improve insulin sensitivity (without promoting insulin release from pancreatic β-cells) and increase peripheral glucose utilization and reduce hepatic glucose production, and as a result, they reduce both preload and afterload on β-cells.2 Unlike sulfonylureas, these agents do not associate with hypoglycaemic side effects.1,3 The above advantages, therefore, make them as a preferred agent for the treatment of T2DM.